Table 3 Clinical monitoring

From: Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations

Evaluation

Notes

Summary of routine evaluations

 Blood (or urine) succinylacetone

 

 Blood NTBC concentration

After initiation of treatment

 Plasma amino acids (phenylalanine, tyrosine)

 

 CBC: hemoglobin, hematocrit, WBC, platelet count

 

 PT/PTT

 

 CMP

 

 AFP

 

 Urine: see renal evaluation below

 

Liver evaluation

 Serum AFP concentration

 

 PT

 

 PTT

 

 ALT/AST/GGT

One of either ALT or AST is good; GGT if patient is symptomatic

 Bilirubin including direct

 

 Albumin

 

 Alkaline phosphatase

For rickets; if elevated, consider wrist radiography, consider vitamin D level

 Imaging: ultrasound with periodic MRI or CT(with contrast)

Modality dependent on individual clinical circumstances (see text)

Renal evaluation

 Ultrasound

 

 Blood chemistries: bicarbonate, BUN, creatinine

 

 Blood calcium and phosphate

 

 Urine analysis

 

 Urine amino acids

 

 Urine calcium, phosphate, creatinine (TRP)

 

 Urine B2-microglobulin

 

Other evaluation

 Nutrition assessment

See text for nutrition

 Developmental evaluation/neuropsychology assessment

By school age or as needed

 Ophthalmology: Slit lamp examination

When symptomatic or at increased risk

  1. AFP, blood alphafetoprotein; ALT, alanine transaminase; AST, aspartate transaminase; BUN, blood urea nitrogen; CBC, complete blood count; CMP, complete metabolic panel plus phosphate; GGT, gamma glutamyl transpeptidase; NTBC, 2-[2-nitro-4-trifluoromethylbenzoyl]-1,3-cyclohexanedione; PT, prothrombin time; PTT, partial thromboplastin time; TRP, tubular reabsorption of phosphate; WBC, white blood count.
  2. Nominal group recommendation: 33% strongly agree, 56% agree and 11% neutral.